Voigt H, Kleeberg U R
Cancer. 1984 May 15;53(10):2058-62. doi: 10.1002/1097-0142(19840515)53:10<2058::aid-cncr2820531009>3.0.co;2-2.
Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP). Treatment consisted of PALA 3000 mg/m2 IV on days 1 and 2, vindesine 3 mg/m2 IV on days 1 and 8, cisplatin 30 mg/m2 IV on days 1 through 5, with treatment cycles repeated on day 21 every 3 weeks. Of 22 patients, 3 had non-visceral disease confined to iuxtaregional tumor growth (Stage III), and 19 had disseminated and/or visceral disease (Stage IV). The male/female sex distribution was 13/9; median age was 45 years. All 22 patients had measurable disease; 21 were evaluable for response and toxicity. Five patients (24%) had a complete response (CR) with a median duration of 5 months, and four patients (19%) had a partial response (PR) with a median duration of 3 months. Seven patients showed disease stabilization (33%) with a median duration of 2 months. Progressive disease was seen in five patients (24%) and was commonly due to widespread visceral disease. CR could be found predominantly in non-visceral disease, whereas PR could be observed in visceral disease also. Survival time from the onset of PVP chemotherapy cannot be estimated finally, since some of the responses are continuing at the present time, and 7 of 21 patients are still alive. Currently, median survival time for responders is 8 months, and for nonresponders, 5 months. Toxicity of PVP chemotherapy is mild to moderate and allows cytotoxic drug administration on an outpatient basis. PVP chemotherapy appears to have significant activity against malignant melanoma and may therefore be an alternative regimen in the management of advanced disease. However, despite the relative high remission rate especially in non-visceral disease, response duration remains disappointingly low.
22例晚期恶性黑色素瘤患者进入一项初步研究，接受丙氨酰谷氨酰胺（PALA）、长春地辛和顺铂（PVP）联合化疗。治疗方案为第1天和第2天静脉注射PALA 3000mg/m²，第1天和第8天静脉注射长春地辛3mg/m²，第1天至第5天静脉注射顺铂30mg/m²，每3周于第21天重复治疗周期。22例患者中，3例为非内脏疾病，局限于近区域肿瘤生长（Ⅲ期），19例为播散性和/或内脏疾病（Ⅳ期）。男女比例为13/9；中位年龄为45岁。所有22例患者均有可测量的疾病；21例可评估疗效和毒性。5例患者（24%）完全缓解（CR），中位缓解持续时间为5个月，4例患者（19%）部分缓解（PR），中位缓解持续时间为3个月。7例患者疾病稳定（33%），中位稳定持续时间为2个月。5例患者（24%）出现疾病进展，常见原因是广泛的内脏疾病。CR主要见于非内脏疾病，而PR在内脏疾病中也可观察到。由于目前一些反应仍在持续，且21例患者中有7例仍存活，因此无法最终估计PVP化疗开始后的生存时间。目前，缓解者的中位生存时间为8个月，未缓解者为5个月。PVP化疗的毒性为轻至中度，允许在门诊进行细胞毒性药物给药。PVP化疗似乎对恶性黑色素瘤有显著活性，因此可能是晚期疾病治疗的替代方案。然而，尽管缓解率相对较高，尤其是在非内脏疾病中，但缓解持续时间仍然低得令人失望。
